Table 1. Treatment and outcome of studies focusing on patients with gastric cancer with positive cytology or peritoneal metastasis treated with intraperitoneal chemotherapeutic.

Author	Year	Trial	Inclusion criteria	Total number of patients	Comparative study	Response rate (%)	Treatment plan	Median overall survival	P value
Ishigami	2010	Phase II	Cyto pos/PM	40	Phase II	56–62	Chemo	22.6
Fujiwara	2012	Phase II	Cyto pos/PM	18	Phase II	62.5–78	Chemo–Surgery–Chemo	24.6
Imano	2012	Phase II	PM	15	Phase II	n.a.	Chemo	15.8
Fushida	2013	Phase II	PM	27	Phase II	22–51.9	Chemo–Surgery–Chemo	16.2
Yamaguchi	2013	Phase II	PM	35	Phase II	68–97	Chemo–Surgery–Chemo	17.6
Ishigami	2017	Phase II	Cyto pos/PM	100	Phase II	64	Chemo–Surgery–Chemo	30.5 months (23.6–37.7)
Ishigami	2018	Phase III	PM	164	IP + IV + S1	76	Chemo	17.7	0.08
					IV + S1		Chemo	15.2
Yonemura	2020	NRCT	Cyto pos/PM	419	no	64.1	Chemo–Surgery–Chemo	CC-0: 20.5 CC-1: 12.0	<0.001

Cyto pos, positive cytology; PM, peritoneal metastasis; NRCT, non-randomized controlled trial; IP, intraperitoneally; IV, intravenously; S1, tegafur/gimeracil/oteracil; n.a., not available.